Skip to search formSkip to main contentSkip to account menu

NN 414

Known as: NN-414, NN414, NN414 cpd 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Bridged Bicyclo Compounds, HeterocyclicCyclic S-OxidesTifenazoxide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Continuous hypothalamic KATP activation blunts glucose counter-regulation in vivo in rats and suppresses KATP conductance in vitro
Aims/hypothesisAcute systemic delivery of the sulfonylurea receptor (SUR)-1-specific ATP-sensitive K+ channel (KATP) opener… 
2010
2010
Effects of cyclooxygenase-2 inhibitor and adenosine triphosphate-sensitive potassium channel opener in syngeneic mouse islet transplantation.
2008
2008
Amplified Hormonal Counterregulatory Responses to Hypoglycemia in Rats After Systemic Delivery of a SUR-1–Selective K+ Channel Opener?
OBJECTIVE— In glucose-sensing neurons, ATP-sensitive K+ channels (KATP channels) are thought to translate metabolic signals into… 
2006
2006
Selective pancreatic ATP-sensitive potassium channel openers for the treatment of glucose homeostasis disorders
Disorders of glucose homeostasis may be associated with severe pathologies such as type 1 and type 2 diabetes, insulinoma… 
2004
2004
Attenuation of hyperinsulinemia by NN414, a SUR1/Kir6.2 selective K-adenosine triphosphate channel opener, improves glucose tolerance and lipid profile in obese Zucker rats.
2004
2004
Openers of ATP-dependent K+-channels protect against a signal-transduction-linked and not freely reversible defect of insulin secretion in a rat islet transplantation model of Type 2 diabetes
Aims/hypothesisWe tested whether chronic overstimulation by levels of hyperglycaemia commonly found in Type 2 diabetes can… 
2004
2004
Improved beta-cell survival and reduced insulitis in a type 1 diabetic rat model after treatment with a beta-cell-selective K(ATP) channel opener.
Treatment with ATP-sensitive K(+) channel openers (KCOs) leads to inhibition of insulin secretion and metabolic "rest" in beta… 
Review
2003
Review
2003
NN-414. Novo Nordisk.
Novo Nordisk is developing NN-414, an orally active beta-cell-selective regulator of insulin release, for the potential treatment… 
2003
2003
NN-414. Novo Nordisk.
Novo Nordisk is developing NN-414, an orally active beta-cell-selective regulator of insulin release, for the potential treatment… 
2002
2002
Potent and selective activation of beta-cell Type ATP-sensitive potassium channels by NN414, a novel diazoxide analogue.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)